Dizocilpine derivatives as peripheral NMDA receptor antagonists
The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.
1. Compound of formula (I):
wherein:
R 1 represents a cyclobutyl group;
R 2 represents a (C 1 -C 10 )alkyl group;
n is 1;
R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 represent a hydrogen atom; and X − is an anionic counterion selected from the group consisting of I − , Cl − , Br − , and OH − .
2. Compound according to claim 1 , wherein R 2 represents a methyl group or an ethyl group.
3. Compound according to claim 1 , wherein R 2 represents a methyl group.
4. Compound according to claim 1 , wherein R 2 represents an ethyl group.
5. Compound according to claim 1 , wherein the anionic counterion X − is selected from the group consisting of I − and Cl − .
6. Compound according to claim 1 , wherein the anionic counterion X − is I − .
7. Compound according to claim 1 , wherein the anionic counterion X − is Cl − .
8. Compound according to claim 1 , wherein the anionic counterion X − is Br − .
9. Compound according to claim 1 , wherein the anionic counterion X − is OH − .
10. Compound according to claim 1 , chosen from:
11. A pharmaceutical composition comprising at least one compound according to claim 1 , and at least one pharmaceutically acceptable excipient.
12. A method for treating a disease or condition in a subject comprising administering to the subject a compound according to claim 1 , wherein the disease or the condition is pulmonary hypertension.
13. A method for treating a disease or condition in a subject comprising administering to the subject a compound according to the claim 1 , wherein the disease or the condition is selected from the group consisting of pulmonary arterial hypertension and thromboembolic pulmonary hypertension.
14. A method for treating a disease in a subject comprising administering to the subject a compound according to claim 1 , wherein the disease is pulmonary arterial hypertension.